《新股消息》建業新生活(09983.HK)今起招股 每手入場費7,273元
由建業地產(00832.HK)分拆的物管公司建業新生活(09983.HK)公布招股詳情,計劃總發行3億股股份,10%在港公開發售。由今日至本周五(8日)公開招股,招股價介乎5.6元至7.2元,每手1,000股,入場費為7,272.55元。該股預計於5月15日上市。法巴為獨家保薦人。
該公司引入高瓴資本為基礎投資者,並認購7,500萬美元(約5.81億港元)股票。
以招股價中位數6.4元計,公司預計集資淨額為17.85億元,當中60%將用於尋求戰略性投資及收購機會;15%將用於建業+平台及優化用戶體驗;15%將用於提升經營效率;以及10%將用於提供營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.